Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 20, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $98.84 to $10,479,200.00.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Luly Jay R., who is President and CEO at Enanta Pharmaceuticals, sold 15,000 shares at $35.35 on Feb. 20, 2015. Following this transaction, the President and CEO owned 491,393 shares meaning that the stake was reduced by 2.96% with the 15,000-share transaction.

The shares most recently traded at $35.22, down $0.13, or 0.38% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 4,500
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 34,500
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 69,500

The average volume for Enanta Pharmaceuticals has been 426,500 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $628.6 million and is part of the health care sector and drugs industry. Shares are down 33.82% year-to-date as of the close of trading on Friday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 7.9. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings

rates Enanta Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Enanta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gigamon (GIMO) - FREE Research Report

Merchant Shehzad, who is Chief Technology Officer at Gigamon, sold 1,500 shares at $20.31 on Feb. 20, 2015. Following this transaction, the Chief Technology Officer owned 84,855 shares meaning that the stake was reduced by 1.74% with the 1,500-share transaction.

The shares most recently traded at $20.21, down $0.10, or 0.47% since the insider transaction. Historical insider transactions for Gigamon go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 5,727
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 5,727
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 10,357

The average volume for Gigamon has been 290,300 shares per day over the past 30 days. Gigamon has a market cap of $647.5 million and is part of the technology sector and computer hardware industry. Shares are up 14.1% year-to-date as of the close of trading on Friday.

Gigamon Inc. designs, develops, and sells products and services that provide customers with visibility and control of network traffic for enterprises and services providers in the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company has a P/E ratio of 165.8. Currently, there are 2 analysts who rate Gigamon a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GIMO - FREE

TheStreet Quant Ratings

rates Gigamon as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full

Gigamon Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Martin Midstream Partners (MMLP) - FREE Research Report

Bondurant Robert D, who is Executive VP and CFO at Martin Midstream Partners, bought 168 shares at $30.72 on Feb. 20, 2015. Following this transaction, the Executive VP and CFO owned 25,013 shares meaning that the stake was boosted by 0.68% with the 168-share transaction.

Booth Chris H, who is VP/General Counsel/Secretary at Martin Midstream Partners, bought 3 shares at $30.72 on Feb. 20, 2015. Following this transaction, the VP/General Counsel/Secretary owned 6,850 shares meaning that the stake was boosted by 0.05% with the 3-share transaction.

Tauscher Randall, who is Executive Vice President/COO at Martin Midstream Partners, bought 144 shares at $30.72 on Feb. 20, 2015. Following this transaction, the Executive Vice President/COO owned 16,588 shares meaning that the stake was boosted by 0.88% with the 144-share transaction.

The shares most recently traded at $30.40, down $0.32, or 1.05% since the insider transaction. Historical insider transactions for Martin Midstream Partners go as follows:

  • 4-Week # shares bought: 840
  • 4-Week # shares sold: 600
  • 12-Week # shares bought: 840
  • 12-Week # shares sold: 600
  • 24-Week # shares bought: 7,156
  • 24-Week # shares sold: 600

The average volume for Martin Midstream Partners has been 210,600 shares per day over the past 30 days. Martin Midstream Partners has a market cap of $1.1 billion and is part of the basic materials sector and energy industry. Shares are up 12.87% year-to-date as of the close of trading on Friday.

Martin Midstream Partners L.P. collects, transports, stores, and markets petroleum products and by-products in the United States Gulf Coast region. The stock currently has a dividend yield of 10.78%. Currently, there are 3 analysts who rate Martin Midstream Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMLP - FREE

TheStreet Quant Ratings

rates Martin Midstream Partners as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full

Martin Midstream Partners Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null